POINTE-CLAIRE, April 2025 — Cielo Verde Inc., one of Quebec’s leading indoor cannabis producers, is pleased to announce its participation in the International Cannabis Business Conference (ICBC) in Berlin, taking place April 29–30, 2025. The event brings together global cannabis leaders, investors, and innovators to explore the future of the industry across borders.
As part of the conference, Cielo Verde will be exhibiting at the ICBC expo with a dedicated booth, where attendees can meet members of the company’s Cultivation and Sales teams and learn more about Cielo Verde’s internationally compliant cannabis offerings.
In addition, Cielo Verde CEO and founder Barry Laxer will be a featured speaker on a high-profile panel focused on “Establishing International Brands in Emerging Cannabis Markets.” The session will cover strategies for building global brand identity, navigating regulatory frameworks, and meeting the unique expectations of international medical consumers.
“We’re honored to join the conversation at ICBC Berlin and share Cielo Verde’s vision on building internationally recognized cannabis brands,” said Laxer. “With recent certifications and growing export capabilities, we see a tremendous opportunity for thoughtful, well-crafted Canadian cannabis to make its mark globally.”
Cielo Verde recently received GACP and IMC-G.A.P. accreditations, positioning the company to expand into regulated international medical markets. Its flagship brand, Bud Lafleur™, has already seen national success in Canada, with launches in Quebec, Ontario, Alberta, and the Atlantic provinces.
About Cielo Verde Québec Inc.
Founded in 2021, Cielo Verde Québec Inc. is a privately held licensed producer of high-quality medical and recreational cannabis. With over 100,000 square feet of indoor cultivation space across two cutting-edge facilities, the company is among the largest indoor producers in Quebec. Cielo Verde holds licenses for cultivation, processing, sales, and cannabis 2.0 products, and is GACP certified for international medical exports.